Faruqi & Faruqi Investigates Potential Claims Against Inovio Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 14 2026
0mins
Should l Buy INO?
Source: Globenewswire
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Inovio Pharmaceuticals, particularly for investors who purchased securities between October 10, 2023, and December 26, 2025, indicating significant legal risks that could impact stock prices and investor confidence.
- Allegations of False Statements: The lawsuit alleges that Inovio and its executives violated federal securities laws by failing to disclose manufacturing deficiencies in its CELLECTRA device, which diminishes the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024, thereby affecting the company's future market prospects.
- FDA Review Dynamics: Although Inovio announced on December 29, 2025, that its INO-3107 Biologics License Application was accepted by the FDA, the agency noted that the company did not provide adequate information to justify eligibility for accelerated approval, leading to a 24.45% drop in stock price, reflecting market concerns over regulatory prospects.
- Investor Rights Protection: Faruq & Faruqi LLP reminds investors that April 7, 2026, is the deadline to apply to become the lead plaintiff in the federal securities class action, emphasizing the importance of investor participation in legal proceedings and potential economic recovery opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.730
Low
3.00
Averages
7.33
High
13.00
Current: 1.730
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Faces Significant Challenges Ahead
- Innovative Drug Development: Inovio Pharmaceuticals is developing a DNA medicine, INO-3107, targeting recurrent respiratory papillomatosis (RRP), with an estimated 14,000 cases annually in the U.S. and a potential peak sales of $1.1 billion, indicating significant market opportunity.
- FDA Approval Hurdles: Although Inovio sought accelerated approval for INO-3107, the FDA rejected this strategy, citing insufficient justification for eligibility, which may delay the drug's market entry and negatively impact future revenue expectations.
- Manufacturing Complexity: The administration of Inovio's DNA medicines requires its proprietary Cellectra electric device, increasing production costs and potentially hindering acceptance among physicians and insurers, thereby limiting commercial rollout speed.
- Regulatory Setbacks: Inovio has faced multiple regulatory setbacks in recent years, including a phase 3 clinical trial failure for VGX-3100, highlighting significant risks in advancing its drug pipeline, which could lead to continued stock price declines in the medium term.
See More
Inovio Pharmaceuticals Class Action Reminder
- Lawsuit Notification: Glancy Prongay Wolke & Rotter LLP reminds investors that April 7, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025.
- Financial Impact: On August 8, 2024, Inovio reported its Q2 2024 financial results, revealing a delay in submitting the BLA for INO-3107 due to manufacturing issues, which caused its stock price to drop by 3.1% to $8.44 per share.
- FDA Review Update: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 application on a standard review timeline instead of an accelerated one, leading to a further 24.45% decline in stock price to $1.73 per share, exacerbating investor losses.
- False Statements Allegation: The class action complaint alleges that Inovio made materially false statements and failed to disclose significant manufacturing deficiencies and the true prospects of the INO-3107 application, severely undermining investor confidence in the company's future.
See More
Inovio Pharmaceuticals Faces Significant Challenges Ahead
- Development Progress: Inovio Pharmaceuticals' candidate drug INO-3107 targets approximately 14,000 cases of recurrent respiratory papillomatosis (RRP) annually, and if approved, it could achieve peak sales of up to $1.1 billion, indicating significant commercial potential.
- Regulatory Hurdles: Although Inovio requested FDA accelerated approval for INO-3107, the FDA rejected this strategy due to insufficient justification, which may delay the drug's market entry and increase the risks faced by the company.
- Manufacturing Complexity: INO-3107 requires administration via Inovio's proprietary Cellectra electric device, which not only raises production costs but may also lower acceptance among physicians and insurers, complicating commercial rollout.
- Historical Setbacks: Inovio has faced multiple regulatory setbacks in recent years, including the failure of the phase 3 clinical trial for VGX-3100, highlighting significant challenges in R&D and market promotion, which could lead to continued stock price declines in the medium term.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which jeopardized the timely submission of the INO-3107 Biologics License Application (BLA) to the FDA, thereby impacting investor confidence.
- Legal Counsel Recommendation: Investors are advised to select law firms with proven success in securities class actions; Rosen Law Firm has extensive experience and recovered over $438 million for investors in 2019 alone, highlighting its capability in this area.
- Investor Rights Protection: Until the class action is certified, investors can choose to retain counsel or remain absent class members, with future compensation not contingent on serving as lead plaintiffs, ensuring their rights are safeguarded.
See More
Inovio Pharmaceuticals Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device manufacturing and overstated prospects for the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first for the number of securities class action settlements in 2017, demonstrating its expertise and success in this field.
- Investor Guidance: Investors are advised to select qualified counsel with a proven track record to ensure effective legal support in the class action, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegation: The complaint alleges that Inovio made false and misleading statements to the market, resulting in investor losses when the truth about manufacturing deficiencies for its CELLECTRA device and insufficient evidence for FDA priority review emerged.
- BLA Filing Delay: Inovio is accused of being unlikely to file the INO-3107 Biologics License Application (BLA) by the second half of 2024, which further undermines investor confidence in the company's future prospects and contributed to a decline in stock price.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits aimed at helping investors recover losses.
See More
Inovio Pharmaceuticals Faces Significant Challenges Ahead
- Innovative Drug Development: Inovio Pharmaceuticals is developing a DNA medicine, INO-3107, targeting recurrent respiratory papillomatosis (RRP), with an estimated 14,000 cases annually in the U.S. and a potential peak sales of $1.1 billion, indicating significant market opportunity.
- FDA Approval Hurdles: Although Inovio sought accelerated approval for INO-3107, the FDA rejected this strategy, citing insufficient justification for eligibility, which may delay the drug's market entry and negatively impact future revenue expectations.
- Manufacturing Complexity: The administration of Inovio's DNA medicines requires its proprietary Cellectra electric device, increasing production costs and potentially hindering acceptance among physicians and insurers, thereby limiting commercial rollout speed.
- Regulatory Setbacks: Inovio has faced multiple regulatory setbacks in recent years, including a phase 3 clinical trial failure for VGX-3100, highlighting significant risks in advancing its drug pipeline, which could lead to continued stock price declines in the medium term.
See More
Inovio Pharmaceuticals Class Action Reminder
- Lawsuit Notification: Glancy Prongay Wolke & Rotter LLP reminds investors that April 7, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025.
- Financial Impact: On August 8, 2024, Inovio reported its Q2 2024 financial results, revealing a delay in submitting the BLA for INO-3107 due to manufacturing issues, which caused its stock price to drop by 3.1% to $8.44 per share.
- FDA Review Update: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 application on a standard review timeline instead of an accelerated one, leading to a further 24.45% decline in stock price to $1.73 per share, exacerbating investor losses.
- False Statements Allegation: The class action complaint alleges that Inovio made materially false statements and failed to disclose significant manufacturing deficiencies and the true prospects of the INO-3107 application, severely undermining investor confidence in the company's future.
See More
Inovio Pharmaceuticals Faces Significant Challenges Ahead
- Development Progress: Inovio Pharmaceuticals' candidate drug INO-3107 targets approximately 14,000 cases of recurrent respiratory papillomatosis (RRP) annually, and if approved, it could achieve peak sales of up to $1.1 billion, indicating significant commercial potential.
- Regulatory Hurdles: Although Inovio requested FDA accelerated approval for INO-3107, the FDA rejected this strategy due to insufficient justification, which may delay the drug's market entry and increase the risks faced by the company.
- Manufacturing Complexity: INO-3107 requires administration via Inovio's proprietary Cellectra electric device, which not only raises production costs but may also lower acceptance among physicians and insurers, complicating commercial rollout.
- Historical Setbacks: Inovio has faced multiple regulatory setbacks in recent years, including the failure of the phase 3 clinical trial for VGX-3100, highlighting significant challenges in R&D and market promotion, which could lead to continued stock price declines in the medium term.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which jeopardized the timely submission of the INO-3107 Biologics License Application (BLA) to the FDA, thereby impacting investor confidence.
- Legal Counsel Recommendation: Investors are advised to select law firms with proven success in securities class actions; Rosen Law Firm has extensive experience and recovered over $438 million for investors in 2019 alone, highlighting its capability in this area.
- Investor Rights Protection: Until the class action is certified, investors can choose to retain counsel or remain absent class members, with future compensation not contingent on serving as lead plaintiffs, ensuring their rights are safeguarded.
See More
Inovio Pharmaceuticals Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device manufacturing and overstated prospects for the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first for the number of securities class action settlements in 2017, demonstrating its expertise and success in this field.
- Investor Guidance: Investors are advised to select qualified counsel with a proven track record to ensure effective legal support in the class action, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegation: The complaint alleges that Inovio made false and misleading statements to the market, resulting in investor losses when the truth about manufacturing deficiencies for its CELLECTRA device and insufficient evidence for FDA priority review emerged.
- BLA Filing Delay: Inovio is accused of being unlikely to file the INO-3107 Biologics License Application (BLA) by the second half of 2024, which further undermines investor confidence in the company's future prospects and contributed to a decline in stock price.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits aimed at helping investors recover losses.
See More
